These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Nifurtimox, a bright future for treatment of Chagas disease]. Wolf A; Boulliat C; Coillot C; Rouault M; Gaillard K; Beranger C; Oliver M Med Trop (Mars); 2011 Apr; 71(2):131-3. PubMed ID: 21695868 [TBL] [Abstract][Full Text] [Related]
4. Drug discovery for chagas disease: A viewpoint. Kratz JM Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074 [TBL] [Abstract][Full Text] [Related]
5. Nifurtimox (Lampit) for Chagas disease. Med Lett Drugs Ther; 2024 Jul; 66(1707):e123-e124. PubMed ID: 39137168 [No Abstract] [Full Text] [Related]
6. [Treatment of Chagas' disease]. Apt W Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147 [No Abstract] [Full Text] [Related]
7. Etiological treatment of chronic Chagas disease. Cançado JR Rev Inst Med Trop Sao Paulo; 2001; 43(3):173-81. PubMed ID: 11452329 [No Abstract] [Full Text] [Related]
11. Antitrypanosomal therapy for chronic Chagas' disease. Bern C N Engl J Med; 2011 Jun; 364(26):2527-34. PubMed ID: 21714649 [No Abstract] [Full Text] [Related]
12. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Filardi LS; Brener Z Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683 [TBL] [Abstract][Full Text] [Related]
13. Enantiomers of nifurtimox do not exhibit stereoselective anti-Trypanosoma cruzi activity, toxicity, or pharmacokinetic properties. Moraes CB; White KL; Braillard S; Perez C; Goo J; Gaspar L; Shackleford DM; Cordeiro-da-Silva A; Thompson RC; Freitas-Junior L; Charman SA; Chatelain E Antimicrob Agents Chemother; 2015; 59(6):3645-7. PubMed ID: 25845874 [TBL] [Abstract][Full Text] [Related]
14. Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina. Sosa Estani S; Segura EL Mem Inst Oswaldo Cruz; 1999; 94 Suppl 1():363-5. PubMed ID: 10677756 [No Abstract] [Full Text] [Related]
16. Chemotherapy of Chagas' disease: status and new developments. Cerecetto H; González M Curr Top Med Chem; 2002 Nov; 2(11):1187-213. PubMed ID: 12171581 [TBL] [Abstract][Full Text] [Related]
17. The efficacy of a novel compound, (e)-1-(4'-bromo-4-biphenylyl)-1-(4-chlorophenyl)-3-dimethylaminoprop-1-ene against Trypanosoma cruzi in mice. Barrett PA; Beveridge E; Bull D; Caldwell IC; Islip PJ; Neal RA; Woods NC Experientia; 1982 Mar; 38(3):338-9. PubMed ID: 6804255 [TBL] [Abstract][Full Text] [Related]
18. 5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies. Cabrera E; Murguiondo MG; Arias MG; Arredondo C; Pintos C; Aguirre G; Fernández M; Basmadjián Y; Rosa R; Pacheco JP; Raymondo S; Di Maio R; González M; Cerecetto H Eur J Med Chem; 2009 Oct; 44(10):3909-14. PubMed ID: 19446929 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of nifurtimox treatment of chronic Chagas disease by means of several parasitological methods. Muñoz C; Zulantay I; Apt W; Ortiz S; Schijman AG; Bisio M; Ferrada V; Herrera C; Martínez G; Solari A Antimicrob Agents Chemother; 2013 Sep; 57(9):4518-23. PubMed ID: 23836179 [TBL] [Abstract][Full Text] [Related]
20. [Recommendations for diagnosis, treatment and follow-up of the Trypanosoma cruzi: human immunodeficiency virus co-infection]. Rev Soc Bras Med Trop; 2006; 39(4):392-415. PubMed ID: 17119760 [No Abstract] [Full Text] [Related] [Next] [New Search]